NEW YORK, March 18, 2024 /PRNewswire/ -- Delcath Systems,
Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an
interventional oncology company focused on the treatment of primary
and metastatic cancers of the liver, is pleased to announce the
appointment of Martha S. Rook as its
new Chief Operating Officer (COO).
Martha S. Rook, Ph.D., is an
experienced industry leader who brings more than 25 years of
academic and industry experience in molecular biology, diagnostics
development, biologics process development and biologics
manufacturing. She joins Delcath from insitro where she served as a
Chief Technical Operations Officer and was responsible for core
research services, facilities and laboratory operations, quality
and project and portfolio management. Prior to insitro, she was
with Sigilon Therapeutics, where she served as Chief Technical
Operations Officer and was responsible for the analytics,
manufacturing, supply chain and quality organizations producing a
biologic-device combination product.
"We are thrilled to welcome Martha, a Senior business leader
with more than 25 years of experience, to the leadership team,"
said Gerard Michel, Chief Executive Officer of Delcath.
"Her extensive knowledge of the technical, business, and regulatory
challenges of supplying complex combination products will be
invaluable as we expand the production of HEPZATO KIT and
CHEMOSAT."
Martha's experience also includes 13 years at MilliporeSigma,
where she held a variety of roles, ultimately serving as vice
president and head of the Gene Editing & Novel Modalities
Business and led a team developing and providing tools and services
for cell and gene therapies from discovery to manufacturing. Martha
received her Ph.D. in biochemistry from MIT and holds a B.S. in chemistry from Texas A&M University. She pursued postdoctoral
studies in neuroscience as a Lefler Fellow at Harvard Medical School's Center for Neurologic
Diseases.
The Company granted Ms. Rook an equity award, previously
approved by the Company's Compensation Committee, as a material
inducement to her employment in accordance with NASDAQ Listing Rule
5635(c)(4). The grant totaled the right to purchase 125,000
shares of the Company's common stock and is subject to the terms
and conditions of the Company's 2023 Inducement Plan
("Plan"). The options were granted on March 18, 2024, and are
subject to an exercise price equal to the closing price
of Delcath's common stock on the grant date.
The options have a ten-year term and vest ratably over the 36-month
period beginning on the Grant Date, (i.e., 1/36th will vest at the
end of each month during said 36-month period), subject to Ms.
Rook's continued service with the Company on each respective
vesting date.
About Delcath Systems, Inc.
Delcath Systems,
Inc. is an interventional oncology company focused on the
treatment of primary and metastatic liver cancers. The Company's
proprietary products, HEPZATO KIT™ (melphalan for Injection/Hepatic
Delivery System), approved for use in the United
States by the Food and Drug Administration, and CHEMOSAT
Hepatic Delivery System for Melphalan percutaneous hepatic
perfusion (PHP), designated under the medical device regulation for
use in Europe and the United Kingdom, are designed
to administer high-dose chemotherapy to the liver while controlling
systemic exposure and associated side effects during a PHP
procedure. For more information regarding HEPZATO KIT and its use,
including Important Safety Information and Boxed Warning, please
visit HEPZATOKIT.com. For more information regarding
CHEMOSAT and its use, please visit Chemosat.com.
Contact:
Investor Relations Contact:
Ben Shamsian Lytham Partners
646-829-9701
shamsian@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/delcath-systems-appoints-martha-s-rook-as-chief-operating-officer-302091999.html
SOURCE Delcath Systems, Inc.